A Phase I/II trial evaluating the combination of ex vivo-expanded γδT cells with trastuzumab demonstrated enhanced tumor regression in HER2+ breast cancer patients, indicating the clinical potential of ADCC-mediated γδT cell therapy (65). This evidence concerns the gene ERBB2 and neoplasm.